Comparative cost-effectiveness of amisulpride and olanzapine in the treatment of schizophrenia in China

References

• van Os J, Kapur S. Schizophrenia. Lancet. 2009;374(9690):635–645.
   PubMed Web of Science ®Google Scholar
• Dziwota E, Stepulak MZ, Włoszczak-Szubzda A, et al. Social functioning and the quality of life of patients diagnosed with schizophrenia. Ann Agric Environ Med. 2018;25(1):50–55.
   PubMed Web of Science ®Google Scholar
• Whiteford HA, Ferrari AJ, Degenhardt L, et al. The global burden of mental, neurological and substance use disorders: an analysis from the Global Burden of Disease Study 2010. PloS One. 2015;10(2):e0116820.
   PubMed Web of Science ®Google Scholar
• WHO. The global burden of disease: 2004 update. WHO; 2018 [cited 2019 Sep 10] Available from: https://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/.
   Google Scholar
• Pennington M, McCrone P. The cost of relapse in schizophrenia. Pharmacoeconomics. 2017;35(9):921–936.
   PubMed Web of Science ®Google Scholar
• Jin H, Mosweu I. The Societal Cost of Schizophrenia: A Systematic Review. Pharmacoeconomics. 2017;35(1):25–42.
   PubMed Web of Science ®Google Scholar
• Barbosa WB, Costa JO, LLP DL, et al. Costs in the treatment of schizophrenia in adults receiving atypical antipsychotics: an 11-year cohort in Brazil. Appl Health Econ Health Policy. 2018;16(5):697–709.
   PubMed Web of Science ®Google Scholar
• Kohn R, Saxena S, Levav I, et al. The treatment gap in mental health care. Bull World Health Organ. 2004;82(11):858–866.
   PubMed Web of Science ®Google Scholar
• Demyttenaere K, Bruffaerts R, Posada-Villa J, et al. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization world mental health surveys. JAMA. 2004;291(21):2581–2590.
   PubMed Web of Science ®Google Scholar
• Chan KY, Zhao -F-F, Meng S, et al. Prevalence of schizophrenia in China between 1990 and 2010. J Glob Health. 2015;5(1):010410.
   PubMed Web of Science ®Google Scholar
• Montgomery W, Liu L, Stensland MD, et al. The personal, societal, and economic burden of schizophrenia in the People’s Republic of China: implications for antipsychotic therapy. Clinicon Econ Outcomes Res. 2013;5:407–418.
   PubMedGoogle Scholar
• Godman B, Grobler C, Van-De-Lisle M, et al. Pharmacotherapeutic interventions for bipolar disorder type II: addressing multiple symptoms and approaches with a particular emphasis on strategies in lower and middle-income countries. Expert Opin Pharmacother. 2019;20(18):2237–2255.
   PubMed Web of Science ®Google Scholar
• Wu J, He X, Liu L, et al. Health care resource use and direct medical costs for patients with schizophrenia in Tianjin, People’s Republic of China. Neuropsychiatr Dis Treat. 2015;11:983–990.
   PubMed Web of Science ®Google Scholar
• Lu Y, Bai Y, Li H, et al. Disease burden research of quetiapine and olanzapine in the treatment of schizophrenia. China J Pharm Econ. 2016;10(7):10–13.
   Google Scholar
• WHO collaborating centre for drug statistics methodology. [cited 2018 Jul 18]. Available from: https://www.whocc.no/atc_ddd_index/?code=N05A.
   Google Scholar
• Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–962.
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Agarwal V, Kishi T, et al. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol Psychiatry. 2013;18(1):53–66.
   PubMed Web of Science ®Google Scholar
• Leucht S, Tardy M, Komossa K, et al. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2012 (5):CD008016.
   PubMed Web of Science ®Google Scholar
• Men P, Yi Z, Li C, et al. Comparative efficacy, safety and cost between amisulpride and olanzapine in treatment of schizophrenia in China: a systematic review, meta-analysis and cost-minimization analysis. BMC Psychiatry. 2018;18. DOI:10.1186/s12888-018-1867-8.
   PubMed Web of Science ®Google Scholar
• Komossa K, Rummel-Kluge C, Hunger H, et al. Amisulpride versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010(1):CD006624.
   PubMed Web of Science ®Google Scholar
• Lin L, Zhao YJ, Zhou HJ, et al. Comparative cost-effectiveness of 11 oral antipsychotics for relapse prevention in schizophrenia within Singapore using effectiveness estimates from a network meta-analysis. Int Clin Psychopharmacol. 2016;31(2):84–92.
   PubMed Web of Science ®Google Scholar
• García-Ruiz AJ, Pérez-Costillas L, Montesinos AC, et al. Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses. Health Econ Rev. 2012;2(1):8.
   PubMedGoogle Scholar
• Takahashi M, Nakahara N, Fujikoshi S, et al. Remission, response, and relapse rates in patients with acute schizophrenia treated with olanzapine monotherapy or other atypical antipsychotic monotherapy: 12-month prospective observational study. Pragmat Obs Res. 2015;6:39.
   PubMed Web of Science ®Google Scholar
• Zhao JP, Shi SX. Chinese guidelines for the prevention and treatment of schizophrenia(version 2); 2015. ISBN 9787830050269.
   Google Scholar
• Ananthapavan J, Nguyen PK, Bowe SJ, et al. Cost-effectiveness of community-based childhood obesity prevention interventions in Australia. Int J Obesity. 2019;43(5):1102–1112.
   Web of Science ®Google Scholar
• Steingard S. Five year Outcomes of tapering antipsychotic drug doses in a community mental health center. Community Ment Health J. 2018;54(8):1097–1100.
   PubMed Web of Science ®Google Scholar
• Life tables for WHO member States. [cited 2018 Jul 18]. Available from: http://www.who.int/gho/countries/chn/en/.
   Google Scholar
• Gatov E, Rosella L, Chiu M, et al. Trends in standardized mortality among individuals with schizophrenia, 1993–2012: a population-based, repeated cross-sectional study. CMAJ. 2017;189(37):E1177E1187.
   PubMed Web of Science ®Google Scholar
• Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford UniversityPress; 2006 [cited 2019 Sep 10]. ISBN: 9780198526629
   Google Scholar
• Lenert LA, Sturley AP, Rapaport MH, et al. Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores. Schizophr Res. 2004;71(1):155–165.
   PubMed Web of Science ®Google Scholar
• Briggs A, Wild D, Lees M, et al. Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation. Health Qual Life Outcomes. 2008;6:105.
   PubMed Web of Science ®Google Scholar
• Lam ETP, Lam CLK, Lai CL, et al. Health-related quality of life of Southern Chinese with chronic hepatitis B infection. Health Qual Life Outcomes. 2009;7:52.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhai J, Wei Q, et al. Cost-effectiveness analysis of psychosocial intervention for early stage schizophrenia in China: a randomized, one-year study. BMC Psychiatry. 2014;14(1):212.
   PubMedGoogle Scholar
• Kwon JS, Tinker AV, Hanley GE, et al. BRCA mutation testing for first-degree relatives of women with high-grade serous ovarian cancer. Gynecol Oncol. 2019;152(3):459–464.
   PubMed Web of Science ®Google Scholar
• National Health Commission of the People’s Republic of China. China’s health statistics yearbook. Beijing: Peking Union Medical College Press; 2018.
   Google Scholar
• Basu A. Cost-effectiveness analysis of pharmacological treatments in schizophrenia: critical review of results and methodological issues. Schizophr Res. 2004;71(2–3):445–462.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal 2013. London: NICE; 2013 [cited 2019 Sep 10]. Available from: https://www.nice.org.uk/process/pmg9/chapter/evidence
   Google Scholar
• Villeneuve K, Potvin S, Lesage A, et al. Meta-analysis of rates of drop-out from psychosocial treatment among persons with schizophrenia spectrum disorder. Schizophr Res. 2010;121(1–3):266–270.
   PubMed Web of Science ®Google Scholar
• Bhanji NH, Chouinard G, Margolese HC. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. Eur Neuropsychopharmacol. 2004;14(2):87–92.
   PubMed Web of Science ®Google Scholar